| Code | CSB-RA004788MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Nebokitug, targeting CCL24 (also known as eotaxin-2), a CC chemokine family member that plays a critical role in eosinophil recruitment and activation. CCL24 binds primarily to the CCR3 receptor and mediates inflammatory responses by attracting eosinophils to sites of allergic inflammation. This chemokine is implicated in various eosinophil-associated disorders, including asthma, atopic dermatitis, allergic rhinitis, and eosinophilic esophagitis, where elevated CCL24 levels correlate with disease severity and tissue eosinophilia.
Nebokitug represents a therapeutic antibody designed to neutralize CCL24 activity, thereby reducing eosinophil-mediated inflammation in allergic and inflammatory conditions. This biosimilar antibody provides researchers with a valuable tool for investigating CCL24-dependent mechanisms in allergic diseases, studying eosinophil biology, and exploring therapeutic interventions targeting the CCL24-CCR3 axis. The antibody enables detailed examination of chemokine signaling pathways and their contribution to inflammatory pathologies in preclinical research models.
There are currently no reviews for this product.